Wertigkeit der 11 C-Cholin-PET/CT in der Primärdiagnostik des Prostatakarzinoms
LicenseStandard (Fassung vom 01.10.2008)
The ability of 11C-Choline and multimodality fusion imaging with integrated PET and contrast-enhanced CT was investigatet to delineate prostate carcinoma within the prostate and differentiate cancer tissue from normal prostate, benign prostate hyperplasia, and focal chronic prostatitis. RESULTS: The SUV of 11C-Choline in PCa tissue was 3.5 +/- 1.3 (mean +/- SD) and significantly higher than that in prostate tissue with benign histopathologic lesions (2.0 +/- 0.6; p<0.001 benign histopathology vs. cancer). A threshold SUV of 2.65 yielded an area under the reciever-operating-characteristic (ROC) curve of 0.89 +/- 0.01 for correctly locating PCa. CONCLUSION: 11C-Choline PET/CT can accurately detect and locate major areas with PCa and differentiate segments with PCa from those with benign hyperplasia, chronic prostatitis, or normal prostate tissue. Within patients with antihormonal treatment 11C-Choline PET/CT diagnostics failed to accurately detect PCa areas within the prostate and could not differentiate between benign and malignant tissue. The maximal tumoral 11C-Choline uptake is related to pT stage.
Subject HeadingsPositronen-Emissions-Tomographie [GND]
Prostatic neoplasms [MeSH]